

Application No. 10/796,522
Response Dated November 13, 2008
Reply to Office Action of August 13, 2008

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the above-identified application. Please cancel claims 1-73.

Claims:

1. - 73. (Cancelled)

74. (New) A therapeutic composition comprising an amyloid-beta (A β) polypeptide linked to a therapeutic non-A β polypeptide, and a sterile pharmaceutically acceptable carrier or excipient,
wherein said therapeutic non-A β polypeptide improves or stabilizes one or more clinical features of a CNS disorder in a patient,
wherein the clinical features of a CNS disorder are selected from the group consisting of cognitive function, memory, behavior, language skills, motor skills and patient rigidity,
wherein the non-A β polypeptide is an antibody,
and wherein the antibody is polyamine modified.

75. (New) The composition of claim 74, wherein the antibody is a monoclonal polyamine modified antibody.

76. (New) The composition of claim 75 wherein the monoclonal polyamine modified antibody has specific binding affinity for amyloid comprising residues 1-39 of SEQ ID NO:1.

77. (New) The composition of claim 74, wherein the non-amyloid-beta (A β) polypeptide polyamine modified antibody is a humanized antibody.